These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27841152)

  • 1. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
    Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
    Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
    Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
    BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
    Greulich T; Kostikas K; Gaga M; Aalamian-Mattheis M; Lossi NS; Patalano F; Nunez X; Pagano VA; Fogel R; Vogelmeier CF; Clemens A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1229-1237. PubMed ID: 29713156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P; Hagedorn-Peinz I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
    Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects.
    Sechaud R; Machineni S; Tillmann HC; Hara H; Tan X; Zhao R; Ren S; Hou J
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):723-731. PubMed ID: 26428357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
    Respir Med; 2021; 180():106311. PubMed ID: 33711782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seebri Neohaler and Utibron Neohaler for COPD.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
    Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
    Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC; Tan EC; Yang MC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.
    Lehmann S; Ringbæk T; Løkke A; Grote L; Hedner J; Lindberg E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():199-210. PubMed ID: 30666100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.